These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27236560)

  • 1. Inhibitors of Angiogenesis.
    Büning H; Hacker UT
    Adv Exp Med Biol; 2016; 917():261-85. PubMed ID: 27236560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical application of therapies targeting VEGF.
    Yancopoulos GD
    Cell; 2010 Oct; 143(1):13-6. PubMed ID: 20887885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis inhibitors: an upcoming therapy for cancer and wet age-related macular degeneration.
    Sweeney K
    Drug Discov Today; 2005 Oct; 10(20):1346-8. PubMed ID: 16253870
    [No Abstract]   [Full Text] [Related]  

  • 4. Emerging therapies for the treatment of neovascular age related macular degeneration.
    Yuan A; Kaiser PK
    Semin Ophthalmol; 2011 May; 26(3):149-55. PubMed ID: 21609228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
    de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
    Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic approaches for targeting tumor angiogenesis.
    Linkous AG; Yazlovitskaya EM
    Anticancer Res; 2012 Jan; 32(1):1-12. PubMed ID: 22213282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor angiogenesis and anti-angiogenic therapies.
    Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
    Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neovascular age-related macular degeneration.
    Veritti D; Sarao V; Lanzetta P
    Ophthalmologica; 2012; 227 Suppl 1():11-20. PubMed ID: 22517121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
    Tarallo V; De Falco S
    Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis and current antiangiogenic strategies for the treatment of cancer.
    Oklu R; Walker TG; Wicky S; Hesketh R
    J Vasc Interv Radiol; 2010 Dec; 21(12):1791-805; quiz 1806. PubMed ID: 20980167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration.
    Broadhead GK; Hong T; Chang AA
    Acta Ophthalmol; 2014 Dec; 92(8):713-23. PubMed ID: 24925048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
    Ferrara N
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-angiogenic therapeutic strategies and inhibition of tumor growth].
    Bachelot T
    Ann Pathol; 1999; 19(5 Suppl):S74-5. PubMed ID: 10599459
    [No Abstract]   [Full Text] [Related]  

  • 15. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
    Fischer C; Mazzone M; Jonckx B; Carmeliet P
    Nat Rev Cancer; 2008 Dec; 8(12):942-56. PubMed ID: 19029957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors.
    Chambers A; Kundranda M; Rao S; Mahmoud F; Niu J
    Curr Oncol Rep; 2021 Jul; 23(9):100. PubMed ID: 34269922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging pharmacologic therapies for wet age-related macular degeneration.
    Ni Z; Hui P
    Ophthalmologica; 2009; 223(6):401-10. PubMed ID: 19622904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Xu L; Mrejen S; Jung JJ; Gallego-Pinazo R; Thompson D; Marsiglia M; Freund KB
    Retina; 2015 Feb; 35(2):176-86. PubMed ID: 25387047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Schachat AP
    Am J Ophthalmol; 2013 Jul; 156(1):1-2.e1. PubMed ID: 23791369
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy.
    Sato Y
    Int J Clin Oncol; 2003 Aug; 8(4):200-6. PubMed ID: 12955574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.